Skip to main content

Redx and AstraZeneca agree research collaboration targeting genetic drivers of tumor growth

Redx and AstraZeneca agree research collaboration targeting genetic drivers of tumor growth

Redx Pharma announced that it has entered into a research collaboration with AstraZeneca to discover and develop new molecules targeting a genetic driver of tumour growth.

The research collaboration will involve Redx Pharma scientists working with AstraZeneca’s Oncology Innovative Medicines group to accelerate the drug discovery process. Redx Pharma will use its early stage drug discovery capabilities to identify novel leads whose further development will be supported by AstraZeneca’s extensive knowledge of the area and strong oncology expertise.

Neil Murray, Chief Executive of Redx Pharma said: “We welcome the opportunity to work closely with AstraZeneca — an organisation that has such a strong research focus. This deal represents a significant development for our oncology business — another major transaction and the first time we’ve had an opportunity to work with the Oncology Innovative Medicines Unit at AstraZeneca. The project is a good fit for both parties and builds on Redx’s strong track record in rapidly developing novel drugs in cancer.”